









Markets
/
Stocks
/
nasdaq-lnsr
/

LENSAR Inc

LNSR

6.070USD

+0.550+9.96%

Close 03/27, 16:00（ET）Quotes delayed by 15 min

64.55MMarket Cap

LossP/E TTM



LENSAR Inc

6.070

+0.550+9.96%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of LENSAR Inc

Currency: USD Updated: 2026-03-26

Key Insights

LENSAR Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 139 out of 209 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 10.00.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

LENSAR Inc's Score

Industry at a Glance

Industry Ranking

139 / 209

Overall Ranking

410 / 4546

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

LENSAR Inc Highlights

StrengthsRisks

LENSAR, Inc. is a commercial-stage medical device company. The Company is focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. Its product portfolio includes the LENSAR Laser System (LLS), and the ALLY Robotic Cataract Laser Treatment System (ALLY). The Company has developed its ALLY Robotic Cataract Laser System as a compact, ergonomic system utilizing a fast dual-modality laser and integrating artificial intelligence (AI) into proprietary imaging and software. ALLY is designed to transform cataract surgery by utilizing the Company’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes its proprietary Streamline software technology, designed to guide surgeons to achieve better outcomes.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 51.29% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 53.49M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 53.49M.

Overvalued

The company’s latest PE is -1.26, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 5.97M shares, decreasing 9.18% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 515.73K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.07.

Analyst Rating

Based on 1 analysts

Strong Buy

Current Rating

10.000

Target Price

+79.86%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-26

The current financial score of LENSAR Inc is 6.35, ranking 154 out of 209 in the Healthcare Equipment & Supplies industry. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 14.32M, representing a year-over-year increase of 5.74%, while its net profit experienced a year-over-year increase of 147.20%.

Score

Industry at a Glance

Previous score

6.35

Change



Financials

4.57

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.52

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

6.53

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.04

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.08

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

LENSAR Inc's Company Valuation

Currency: USD Updated: 2026-03-26

The current valuation score of LENSAR Inc is 6.73, ranking 154 out of 209 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -1.26, which is -11.48% below the recent high of -1.12 and -390.25% above the recent low of -6.19.

Score

Industry at a Glance

Previous score

6.73

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 139/209

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-26

No earnings forecast score is currently available for LENSAR Inc. The Healthcare Equipment & Supplies industry's average is 7.78. The average price target is 15.00, with a high of 15.00 and a low of 15.00.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 1 analysts

Strong Buy

Current Rating

10.000

Target Price

+79.86%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

LENSAR Inc

LNSR

Boston Scientific Corp

BSX

Intuitive Surgical Inc

ISRG

Edwards Lifesciences Corp

Veeva Systems Inc

VEEV

Thermo Fisher Scientific Inc

TMO

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-26

The current price momentum score of LENSAR Inc is 6.71, ranking 105 out of 209 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 10.00 and the support level at 3.27, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.65

Change

0.06

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(1)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.708

Sell

RSI(14)

23.201

Sell

STOCH(KDJ)(9,3,3)

17.261

Buy

ATR(14)

0.843

High Vlolatility

CCI(14)

-58.240

Neutral

Williams %R

89.157

Oversold

TRIX(12,20)

-2.487

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

5.760

Buy

MA10

6.455

Sell

MA20

9.084

Sell

MA50

10.932

Sell

MA100

11.042

Sell

MA200

11.781

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-26

The current institutional shareholding score of LENSAR Inc is 3.00, ranking 135 out of 209 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 49.99%, representing a quarter-over-quarter increase of 5.95%. The largest institutional shareholder is Brandes Investmen, holding a total of 856.22K shares, representing 7.17% of shares outstanding, with 55.19% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

North Run Capital, LP

1.10M

Brandes Investment Partners, L.P.

Star Investors

777.70K

+37.99%

Curtis (Nicholas T)

792.29K

BlackRock Institutional Trust Company, N.A.

575.55K

+7.60%

Link (William J)

543.27K

-1.34%

The Vanguard Group, Inc.

Star Investors

507.60K

+0.29%

Connaughton (Alan B.)

279.22K

Lindstrom (Richard L)

239.04K

-2.99%

Dimensional Fund Advisors, L.P.

224.93K

Geode Capital Management, L.L.C.

217.89K

-0.68%

Risk Assessment

Currency: USD Updated: 2026-03-26

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of LENSAR Inc is 4.05, ranking 113 out of 209 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.99. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. LENSAR Inc’s latest ESG disclosure leads the Healthcare Equipment & Supplies industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.